Terms: = Sarcomas AND ACVR2A, ACVR2, 92, ENSG00000121989, ACTRII, P27037 AND Treatment
711 results:
1. Pembrolizumab versus placebo as adjuvant therapy in resected stage IIB or IIC melanoma: Outcomes in histopathologic subgroups from the randomized, double-blind, phase 3 KEYNOTE-716 trial.
Schadendorf D; Luke JJ; Ascierto PA; Long GV; Rutkowski P; Khattak A; Del Vecchio M; de la Cruz-Merino L; Mackiewicz J; Sileni VC; Kirkwood JM; Robert C; Grob JJ; Dummer R; Carlino MS; Zhao Y; Kalabis M; Krepler C; Eggermont A; Scolyer RA
J Immunother Cancer; 2024 Mar; 12(3):. PubMed ID: 38485189
[TBL] [Abstract] [Full Text] [Related]
2. Clinical and surgical effectiveness of the multi-disciplinary standardized management model in the treatment of retroperitoneal liposarcoma: Evidence-based clinical practice experience from Fudan Zhongshan.
Fan P; Tao P; Wang J; Wang Z; Hou Y; Zhou Y; Lu W; Ma L; Zhang Y; Tong H
Surgery; 2024 May; 175(5):1368-1376. PubMed ID: 38395638
[TBL] [Abstract] [Full Text] [Related]
3. Analysis of clinical factors impacting recurrence in myxofibrosarcoma.
Chen W; Ye M; Sun Y; Wei Y; Huang Y
Sci Rep; 2024 Feb; 14(1):3903. PubMed ID: 38365844
[TBL] [Abstract] [Full Text] [Related]
4. A novel nomogram and recursive partitioning analysis for predicting cancer-specific survival of patients with subcutaneous leiomyosarcoma.
Ji Q; Hu H; Li S; Tang J
Sci Rep; 2024 Feb; 14(1):2861. PubMed ID: 38311615
[TBL] [Abstract] [Full Text] [Related]
5. Efficacy and safety of 'Second Adjuvant' therapy with BRAF/MEK inhibitors after local therapy for recurrent melanoma following adjuvant PD-1 based immunotherapy.
Taylor AM; McKeown J; Dimitriou F; Jacques SK; Zimmer L; Allayous C; Yeoh HL; Haydon A; Ressler JM; Galea C; Woodford R; Kahler K; Hauschild A; Festino L; Hoeller C; Schwarze JK; Neyns B; Wicky A; Michielin O; Placzke J; Rutkowski P; Johnson DB; Lebbe C; Dummer R; Ascierto PA; Lo S; Long GV; Carlino MS; Menzies AM
Eur J Cancer; 2024 Mar; 199():113561. PubMed ID: 38278009
[TBL] [Abstract] [Full Text] [Related]
6. Functional or radical surgical treatment of laryngeal chondrosarcoma, analysis of survival and prognostic factors: A REFCOR and NetSarc-ResOs multicenter study of 74 cases.
Gazda P; Baujat B; Sarini J; Gomez-Brouchet A; Philouze P; Moya-Plana A; Malard O; Fakhry N; De Mones Del Pujol E; Garrel R; Page C; Mouawad F; Vaz E; Evrard D; Bach C; Dufour X; Lelonge Y; Schultz P; Mauvais O; Brenet E; Vergez S; Atallah S
Eur J Surg Oncol; 2024 Feb; 50(2):107315. PubMed ID: 38219696
[TBL] [Abstract] [Full Text] [Related]
7. Diagnostic challenges in low-grade central osteosarcoma.
Khal AA; Aiba H; Righi A; Gambarotti M; Atherley O'Meally AO; Manfrini M; Donati DM; Errani C
Bone Joint J; 2024 Jan; 106-B(1):99-106. PubMed ID: 38160683
[TBL] [Abstract] [Full Text] [Related]
8. Surgeon Perspectives on the Management of Aborted Cancer Surgery: Results of a Society of Surgical Oncology Member Survey.
Lopez-Aguiar AG; Sarna A; Wells-DiGregorio S; Huang E; Kneuertz PJ; Beane J; Kim A; Ejaz A; Pawlik TM; Cloyd JM
Ann Surg Oncol; 2024 Apr; 31(4):2295-2302. PubMed ID: 38127216
[TBL] [Abstract] [Full Text] [Related]
9. Epidemiology, site-specific characteristics and survival of carcinosarcoma: a retrospective study based on SEER database.
Tang LS; Zhou YW; Wang JL; Zhang GX; Xu CH; Liu JY; Qiu M
BMJ Open; 2023 Dec; 13(12):e077974. PubMed ID: 38101828
[TBL] [Abstract] [Full Text] [Related]
10. Necrotizing apoptosis-related genes prognosis and treatment effect analysis of osteosarcoma in children.
Chen Y; Wu L; Li Y; Zheng J; Zhong S; Gu S; Chen J
J Gene Med; 2024 Jan; 26(1):e3646. PubMed ID: 38100138
[TBL] [Abstract] [Full Text] [Related]
11. Meta-analysis of 5-day preoperative radiotherapy for soft tissue sarcoma (5D-PREORTS).
Cury FL; Viani GA; Gouveia AG; Freire CVS; Grisi GA; Moraes FY
Radiother Oncol; 2024 Jan; 190():109935. PubMed ID: 37884194
[TBL] [Abstract] [Full Text] [Related]
12. Indeterminate pulmonary nodules in non-rhabdomyosarcoma soft tissue sarcoma: A study of the European paediatric Soft Tissue Sarcoma Study Group.
Giraudo C; Schoot R; Cardoen L; Stramare R; Coppadoro B; Bisogno G; Bouhamama A; Brennan B; Brisse HJ; Orbach D; Coma A; Di Paolo PL; Fayard C; McDonald L; Moalla S; Morosi C; Pace E; Tang V; van Noesel MM; Ferrari A; van Rijn R
Cancer; 2024 Feb; 130(4):597-608. PubMed ID: 37846799
[TBL] [Abstract] [Full Text] [Related]
13. Zoledronic Acid Add-on Therapy for Standard-Risk Ewing Sarcoma Patients in the Ewing 2008R1 Trial.
Koch R; Haveman L; Ladenstein R; Brichard B; Jürgens H; Cyprova S; van den Berg H; Hassenpflug W; Raciborska A; Ek T; Baumhoer D; Egerer G; Kager L; Renard M; Hauser P; Burdach S; Bovee JVMG; Hong AM; Reichardt P; Kruseova J; Streitbürger A; Kühne T; Kessler T; Bernkopf M; Butterfaß-Bahloul T; Dhooge C; Bauer S; Kiss J; Paulussen M; Bonar F; Ranft A; Timmermann B; Rascon J; Vieth V; Kanerva J; Faldum A; Hartmann W; Hjorth L; Bhadri VA; Metzler M; Gelderblom H; Dirksen U
Clin Cancer Res; 2023 Dec; 29(24):5057-5068. PubMed ID: 37843857
[TBL] [Abstract] [Full Text] [Related]
14. Clinicopathological Characteristics, Survival Outcomes, and Prognostic Factors in Adult Patients With Sinonasal Rhabdomyosarcoma: Insights from a Retrospective Cohort Study.
Durzynska M; Dos Santos FLC; Michalek IM
Anticancer Res; 2023 Oct; 43(10):4517-4524. PubMed ID: 37772581
[TBL] [Abstract] [Full Text] [Related]
15. ErbB2 (HER2)-CAR-NK-92 cells for enhanced immunotherapy of metastatic fusion-driven alveolar rhabdomyosarcoma.
Heim C; Moser LM; Kreyenberg H; Bonig HB; Tonn T; Wels WS; Gradhand E; Ullrich E; Meister MT; Koerkamp MG; Holstege FCP; Drost J; Klusmann JH; Bader P; Merker M; Rettinger E
Front Immunol; 2023; 14():1228894. PubMed ID: 37662907
[TBL] [Abstract] [Full Text] [Related]
16. Annual report of the Committee on Gynecologic Oncology, the Japan Society of Obstetrics and Gynecology: Annual Patient Report for 2020 and Annual treatment Report for 2015.
Yoshino K; Kurita T; Takahashi F; Nagase S;
J Obstet Gynaecol Res; 2023 Nov; 49(11):2584-2592. PubMed ID: 37602964
[TBL] [Abstract] [Full Text] [Related]
17. Brentuximab vedotin with AVD for stage II-IV HIV-related Hodgkin lymphoma (AMC 085): phase 2 results from an open-label, single arm, multicentre phase 1/2 trial.
Rubinstein PG; Moore PC; Bimali M; Lee JY; Rudek MA; Chadburn A; Ratner L; Henry DH; Cesarman E; DeMarco CE; Costagliola D; Taoufik Y; Ramos JC; Sharon E; Reid EG; Ambinder RF; Mitsuyasu R; Mounier N; Besson C; Noy A; ;
Lancet Haematol; 2023 Aug; 10(8):e624-e632. PubMed ID: 37532416
[TBL] [Abstract] [Full Text] [Related]
18. Clinical features of uterine sarcomas presenting mainly with uterine masses: a retrospective study.
Zhu M; Chen S
BMC Womens Health; 2023 Jul; 23(1):394. PubMed ID: 37496042
[TBL] [Abstract] [Full Text] [Related]
19. Operative treatment and Outcomes of Pediatric Patients with an Extremity Bone Tumor: A Secondary Analysis of the PARITY Trial Data.
Bozzo A; Yeung CM; Van De Sande M; Ghert M; Healey JH;
J Bone Joint Surg Am; 2023 Jul; 105(Suppl 1):65-72. PubMed ID: 37466582
[TBL] [Abstract] [Full Text] [Related]
20. Automated Segmentation of Sacral Chordoma and Surrounding Muscles Using Deep Learning Ensemble.
Boussioux L; Ma Y; Thomas NK; Bertsimas D; Shusharina N; Pursley J; Chen YL; DeLaney TF; Qian J; Bortfeld T
Int J Radiat Oncol Biol Phys; 2023 Nov; 117(3):738-749. PubMed ID: 37451472
[TBL] [Abstract] [Full Text] [Related]
[Next]
